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Abstract: 
A relationship between adipose tissue and erythropoiesis is believed to exist. The 
adipose tissue secretes several adipokines, some of which are known to interfere with 
erythropoiesis. Adipocytes are also capable of synthesizing hepcidin, the principal regulator 
of iron availability, but it is not completely clarified if this hepcidin synthesis is stimulated by 
inflammation, hypoxia or by BMP/SMAD pathway. 
We aimed to understand how an increasing erythropoietic stimuli affects the 
expression of some inflammatory cytokines, of iron metabolism and erythropoiesis, in both 
visceral (VAT) and subcutaneous (SAT) adipose tissue. 
We performed a 6 weeks follow-up study in lean, adult, normotensive rats submitted 
to erythropoietic stimuli, by administering two high doses of recombinant human 
erythropoietin (rHuEPO) during the last 3 weeks of the protocol. The rats were randomly 
divided in 3 groups – control, rHuEPO200 and rHuEPO600. Hematological and biochemical 
evaluations, including markers of renal function, inflammation, iron status and lipid profile, 
were done at starting and at the end of the protocol. The gene expression of erythropoietic 
and iron regulatory proteins, namely, hepcidin, interleukin (IL)-6, bone morphogenetic 
protein (BMP)6, EPO receptor (EPOR) and ferritin, by the VAT and SAT, were executed.  
In both rHuEPO groups was observed an increase in several erythrocytes 
parameters that was higher for the rHuEPO600 group. Concerning SAT, both groups 
presented a significant overexpression of hepcidin and ferritin genes and an under 
expression of BMP6 and EPOR genes; IL-6 gene was only overexpressed in the 
rHuEPO600 group. For the VAT, in the rHuEPO200 group we found an overexpression of 
hepcidin, IL-6 and ferritin and under expression of BMP6 and EPOR genes; in the 
rHuEPO600 group, all the 5 studied genes were under expressed, presenting the lower 
expression of hepcidin and IL-6 genes a positive significant genes correlation. 
In summary, the BMP/SMAD pathway does not seem to have an important role in 
the regulation of hepcidin expression in adipocyte. When submitted to erythropoietic stimuli, 
the VAT and SAT respond differently. In VAT, a higher erythropoietic stimuli associates with 
a lower expression of hepcidin and IL-6 that correlated positively with each other, 
suggesting that under high erythropoietic stimuli, IL-6 and hepcidin expression are tightly 
related.  
Key-words: Erythropoiesis, iron metabolism, adipose tissue genetic expression.  
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Resumo: 
 O tecido adiposo e o processo eritropoiético parecem estar intimamente 
associados. O tecido adiposo secreta várias adipocinas, algumas das quais interferem com 
a eritropoiese. Os adipócitos são também capazes de sintetizar hepcidina, o principal 
regulador da biodisponibilidade do ferro, contudo não é totalmente claro se esta síntese é 
estimulada pelo processo inflamatório, hipoxia ou pela via BMP/SMAD. 
 O nosso objetivo foi tentar compreender de que forma um estímulo eritropoético 
afeta a expressão de citocinas inflamatórias, o metabolismo do ferro e da eritropoiese, no 
tecido adiposo visceral (TAV) e subcutâneo (TAS).  
 Assim, realizou-se um estudo longitudinal (6 semanas) com ratos adultos, de peso 
e tensão arterial normais, submetidos a um estímulo eritropoético por administração de 
doses elevadas de eritropoietina recombinante humana (rHuEPO) administradas durante 
as últimas 3 semanas. Os ratos foram aleatoriamente divididos em 3 grupos – controlo, 
rHuEPO200 e rHuEPO600. Foram efetuadas avaliações hematológicas e bioquímicas 
(hemograma, marcadores da função renal, inflamação, metabolismo do ferro e perfil 
lipídico) no início e no final do estudo. Foi determinada a expressão génica, no TAV e no 
TAS, de proteínas reguladoras do metabolismo do ferro e da eritropoiese (hepcidina, 
interleucina (IL)-6, proteína morfogénica óssea (BMP)6, recetor da EPO (EPOR) e ferritina).  
 Nos grupos rHuEPO observou-se um aumento no valor de eritrócitos, que foi maior 
no grupo rHuEPO600. No TAS, ambos os grupos apresentaram uma sobre-expressão dos 
genes da hepcidina e da ferritina e uma sub-expressão de BMP6 e EPOR; o gene da IL-6 
encontrava-se sobre-expresso apenas no grupo rHuEPO600. No TAV observou-se, para o 
grupo rHuEPO200, uma sobre-expressão dos genes da hepcidina, IL-6 e ferritina, e uma 
sub-expressão dos genes BMP-6 e EPOR; no grupo rHuEPO600 foi observada uma sub-
expressão de todos os 5 genes, apresentando a expressão significativamente mais baixa 
dos genes de hepcidina e de IL-6, uma correlação positiva significativa. 
 Resumindo, a via BMP/SMAD não parece ser importante na regulação da 
expressão de hepcidina no tecido adiposo. Quando submetidos a um estímulo 
eritropoético, o TAV e o TAS respondem de forma diferente. No TAV, um estímulo 
eritropoético maior associa-se a uma menor expressão dos genes da hepcidina e da IL-6, 
que se correlacionam positivamente, sugerindo que sobre um forte estímulo eritropoético, 
a expressão dos dois genes está fortemente relacionada. 
Palavras-chave: Eritropoiese, metabolismo do ferro, expressão genética, tecido adiposo. 
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Chapter 1 – Introduction 
 
The purpose of this chapter is to explain the linkage between the adipose tissue, iron 
metabolism and erythropoiesis. We will focus the erythropoiesis process, the iron 
metabolism, the characteristics of the adipose tissue and its potential contribution to iron 
bioavailability and to erythropoiesis.  
1.1 – Erythropoiesis 
 
Erythropoiesis is the process of continuous production of erythrocytes, the cells 
responsible for the transport of oxygen from the lungs to oxygen dependent tissues and for 
the mediation of carbon dioxide removal from the tissues. Red blood cells (RBCs) represent 
40% to 45% of total blood volume and the mean lifespan of a RBC is 120 days. Everyday 
about 1% of circulating senescent RBCs are removed and, to replace them, the body 
produces approximately 2.0 x 1011 cells every day. This is sustained by hematopoietic stem 
cells, which are characterized by their ability to self-renew, differentiate, proliferate and give 
rise to all types of mature blood cells (1, 2).  
Erythropoiesis starts in the yolk sac, around the 21st day of gestation, and erythroid 
cells can be found in multilineage colonies, colony forming unit – granulocytes, erythrocytes, 
monocytes and megakaryocytes (CFU-GEMM). From this multilineage colonies appears 
the erythroid cell, the burst-forming unit – erythroid (BFU-e) that in a later mature stage 
gives rise to colony-forming unit – erythroid (CFU-e). This CFU-e differentiates into 
proerythroblasts and erythroblasts that will mature into reticulocytes and, finally, into 
erythrocytes. The reticulocytes extrude their nucleus and complete the synthesis of 
hemoglobin (HGB) giving rise to the mature cell, the erythrocyte (Figure 1) (1, 3). 
 
Figure 1 - Erythroid differentiation (3). 
BFU-e: burst-forming unit erythroid; CFU-e: colony-forming unit erythroid; CMP: 
common myeloid progenitor; HSC: hematopoietic stem cell; MEP: megakaryocyte-
erythroid progenitor. 
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The first recognizable erythroid precursor in the bone marrow is the pro-erythroblast. 
This is a large cell with dark blue cytoplasm, central nucleus with nucleoli and slightly 
clumped chromatin (Figure 1). By cell division, the pro-erythroblasts give rise to smaller 
cells called erythroblasts that will proliferate and differentiate from basophilic erythroblast to 
polychromatic erythroblast and finally to orthochromatic erythroblast. They contain 
progressively more hemoglobin in the cytoplasm, their size decreases and the nuclear 
chromatin becomes more condensed (Figure 1). In the orthochromatic erythroblasts the 
nucleus is extruded and the resulting cell is the reticulocyte that contains some ribosomal 
RNA and is still capable of hemoglobin synthesis. This cell stains pale blue, as some RNA 
is still present (Figure 1). It is larger than the erythrocyte and stays in the bone marrow 
before entering the peripheral blood, where it circulates 1-2 days before maturing into 
erythrocytes. These non-nucleated biconcave cells stain pink and RNA is completely lost 
(Figure 1). Mature erythrocytes have a diameter of 6-8 µm and their biconcave shape 
creates a large surface for gas exchange and allows them to circulate through the 
microcapillaries of the vascular network. One proerythroblast, usually, gives rise to 8-16 
mature erythrocytes (2). 
Erythropoiesis is regulated by the hormone erythropoietin (EPO), which stimulates the 
terminal proliferation and differentiation of BFU-e and CFU-e progenitors. EPO activates 
intracellular signaling by binding to its receptor (EPOR), expressed on the erythroid cell 
surface. EPO acts on both BFU-e and CFU-e cells, but the last one shows greater sensitivity 
to EPO (4). BFU-e cells respond to other factors besides EPO, including stem cell factor 
(SCF), insulin-like growth factor-1 (IGF-1), granulocyte macrophage colony-stimulating 
factor (GM-CSF), interleukin-3 (IL-3) and IL-9. Apparently, the first phase of CFU-e erythroid 
differentiation is highly EPO dependent, decreasing EPO sensitivity as erythroid cells 
mature (1). 
For a normal erythropoiesis some erythropoietic nutrients are needed, like: iron (for the 
formation of hemoglobin), B12 vitamin and folic acid (for the synthesis of DNA), and 
aminoacids (for the synthesis of proteins) (2).   
Inflammation may disturb erythropoiesis, by reducing erythropoiesis, the life span of 
erythrocytes and by altering iron metabolism through the iron-modulating peptide, hepcidin. 
In fact, inflammatory cytokines, particularly IL-6 and IL-1, that are increased in inflammatory 
states, lead to increased production of hepcidin that will reduce the absorption of iron from 
the gut and the release of iron from macrophages that is needed for hemoglobin synthesis 
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(4). Tumor necrosis factor alpha (TNF-alpha) and interferon-gamma (IFN-ƴ), also increased 
in inflammatory conditions, are known to inhibit erythropoiesis. Moreover, the activation of 
inflammatory cells by releasing reactive oxygen species, contribute to the development of 
oxidative stress which might induce oxidative damages to RBCs, favoring its removal.     
1.1.1 – Erythropoietin 
 
Erythropoietin is a 30.4 κDa glycoprotein with four carbohydrate residues. In fetal and 
neonatal life the hepatocyte is the prime source of EPO and this capacity continues in adult 
life, synthesizing, however, only a small amount of EPO; indeed, the major source of EPO 
in the adult comes from the kidney. In experimental animals, the site of EPO production is 
also the kidney. EPO is produced by specialized peritubular cells, in the proximal tubular 
region. The gene responsible for the expression of EPO has been demonstrated in the 
kidney and in various extrarenal locations (2, 4).  
The regulation of erythropoiesis is achieved by an oxygen-sensing system. Actually, 
the EPO gene is under the regulation of the hypoxia inducible factor 1 alpha (HIF-1α), which 
is activated during hypoxia. When the oxygen tension is reduced in the kidney, the α-
subunits of HIF-1 accumulate and link with HIF-1β (hypoxia inducible factor 1 beta) forming 
heterodimers that activate the hypoxia-response genes, namely the EPO gene. Androgenic 
steroids, anabolic steroids and cobaltous chloride also stimulate EPO production by an 
unknown mechanism (4). 
Erythropoietin interacts with EPO receptor (EPOR), which is located on the surface of 
erythroid cells in the marrow, promoting the production of erythrocytes by different 
transduction pathways. The first erythroid cells presenting EPOR are the later BFU-e cells. 
The EPOR are not expressed in the last cells of the maturation process, the reticulocytes 
and mature erythrocytes. EPOR are expressed, therefore, on the erythropoietin responsive 
cells (ERC), which are: later BFU-e, the CFU-e and proerythroblasts (1, 4).  
EPOR contains two polypeptide chains on its extracellular component. Binding of Epo 
to its receptor induces receptor homodimerization and autophosphorylation of the receptor-
associated Janus kinase 2 (JAK2). Activated JAK2 mediates the phosphorylation of key 
tyrosine residues on the distal cytoplasmic region of EPOR, which then serve as docking 
sites for downstream effectors, including signal transducer and activation of transcription 
protein 5 (STAT5) and phosphatidylinositol 3 kinase (PI3 kinase). Activated STAT5 
homodimerizes and translocates to the nucleus. This transmission of the signal to the 
nucleus prevents apoptosis and allows the cell maturation into erythrocytes. Another effect 
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of EPO is to increase the size of ERC population (1, 4). Other intracellular signal 
transduction pathways are the mitogen-activated protein (MAP) kinase, the 
phosphatidylinositol 3 (PI3) kinase and the phosphoinositide-specific phospholipase Cγ 
(PLCγ) pathways (Figure 2).  
Accumulating evidence indicates that all the hematopoietic growth factors and 
cytokines are able to activate simultaneously all the major signal transduction pathways. 
The JAK/STAT pathway is implicated in IL-3, IL-6, EPO and GM-CSF signaling (5), the MAP 
kinase pathway in EPO, GM-CSF, G-CSF and IL-3 signaling (6), and the PI-3 kinase 
pathway in EPO, IL-6, GM-CSF, G-CSF and M-CSF signaling (7).  
 
 
Figure 2 - Erythropoietin receptor signaling via Jak/Stat pathway (8). 
 
 
Akt: V-akt murine thymoma viral oncogene homolog 1; EPO: erythropoietin; JAK-2:  
Janus kinase 2; JH: Jack homology; MAP: mitogen-activated protein; RBC – red blood 
cell; STAT - signal transducer and activation of transcription protein.  
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1.2 – Iron metabolism   
 
Iron is needed for HGB production, at the later stages of erythroid differentiation and 
maturation. To produce 200 billion of new erythrocytes every day, 20-25mg of iron are 
required. From a normal diet providing 10mg of iron daily, only 1mg is absorbed (~5-10% 
of dietary iron); the major source of iron comes from recycling iron from senescent 
erythrocytes, which are phagocytized by reticuloendothelial macrophages (9). The iron from 
diet only covers the real loss of iron that represents about 1-2mg/day (Figure 3) (10).  
 
 
Iron enters the system in three forms: ferrous (Fe2+), ferric (Fe3+) and heme. It is 
absorbed in the proximal duodenum by enterocytes. Fe3+ is reduced to Fe2+ by the mucosal 
ferrireductase duodenal cytochrome b (Dcytb), which is present in the apical surface of the 
duodenum cells; Fe2+ enters the enterocytes by a facilitated transport mechanism, mediated 
by the divalent metal transporter 1 (DMT1) (Figure 4). Protein and mRNA levels of Dcytb 
are elevated in iron deficiency and hypoxia, favoring iron absorption, and are decreased in 
Figure 3 - Iron homeostasis and major pathways of iron traffic (approximate values) (10). 
Fe3+: ferric iron; TF: transferrin. 
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iron overload. Protein and DMT1 mRNA levels are decreased when cellular iron is 
increased, and decrease when cells are iron deficient. This regulation is achieved by binding 
iron response proteins (IRPs) to the iron responsive element (IRE) within the 3 prime 
untranslated region (3’-UTR) of the C-terminal end of DMT1, protecting the mRNA from 
endocytic cleavage, increasing mRNA half-life and consequently increasing the amount of 
translated protein (10, 11).  
Heme iron enters directly into enterocytes as an intact iron-protoporphyrin complex, 
possibly by endocytosis or by binding to a haem receptor on the brush border of 
enterocytes, the haem carrier protein 1 (HCP1) , that was recently described. Inside the 
cell, it is most likely to be cleaved by the intracellular microsomal enzyme, haem-oxygenase 
1 (HO1), releasing ferrous iron and forming biliverdin (Figure 4) (10).  
 
Figure 4 - Absorption of iron through enterocytes (12). 
 
Dcytb - duodenal cytochrome b; DMT1 - divalent metal transporter 1; HCP1 - haem 
carrier protein 1; HO1 - haem oxygenase-1; IREG1 - Iron-regulated transporter-1; Tf – 
transferrin. 
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Inside the enterocytes the iron can be stored as ferritin or transferred across the 
basolateral membrane of the enterocyte to the bloodstream. Ferritin is a spherical protein 
ubiquitously expressed and its main function is to store and sequester excess iron in a 
soluble, non-toxic form. There are two forms of this shell form protein with 24 subunits, light 
(L) and heavy (H) chains with a central cavity able to store up to 4500 iron atoms in the form 
of hydrous ferric oxide phosphate. The two chains have different properties, while L-chains 
are important for core iron binding, H-chains confer ferroxidase activity needed for iron 
incorporation. Ferritin also have an IRE in the 5’ UTR of its mRNA; in case of iron deficiency, 
IPRs bind to IRE and block translation, increasing cellular iron availability (10).  Because of 
its capacity to sequester iron, ferritin has also an anti-oxidant function. It is regulated by 
cytokines, like IL-6, IL-1 and IFN- ƴ (13, 14).   
Ferroportin (FPN1), also known as iron-regulated transporter-1 (IREG1), is a tubular 
transmembrane protein expressed in the basolateral membrane of the duodenal enterocyte 
that mediates iron efflux to the circulation. FPN1 is also found in the liver, spleen and 
reticuloendothelial macrophages. FPN1 mRNA also contains an IRE in its 5’ UTR, and, it is 
also controlled by iron; duodenal FPN1 mRNA and its protein expression are decreased in 
iron overload and increased in iron deficiency. FPN1 is also influenced by inflammation and 
is post-transcriptionally regulated by hepcidin, which binds to FPN1 inducing its 
internalization and lysosomal degradation (10, 15, 16).   
Transferrin (TF), a 80kDa monomeric glycoprotein mainly produced by the liver, 
transports iron between the locals where iron is absorbed and the local of storage and 
usage. It contains two globular domains, each one with a high affinity binding site to one 
molecule of Fe3+. This affinity is dependent on pH; iron is released from TF at pH lower than 
6.5, while at the physiological pH 7.4, iron is strongly bound to TF. This plays an important 
role on the mechanism of iron release from TF (10).  
Transferrin has also the ability to bind to other divalent metals, but with less affinity 
(copper, cobalt, manganese and cadmium). A requisite for iron to bind to TF is a 
simultaneous binding of a bicarbonate or carbonate to arginine and threonine residues. In 
circulation TF can be free of iron (apotransferrin) or to be linked to two molecules of iron 
(diferric transferrin).    
TF transporting iron interacts with transferrin receptor (TFR) to transport iron into the 
cell, where DMT1 facilitates the release of iron from TF and its reduction from Fe 3+ to Fe 2+ 
by STEAP3, a ferrireductase; then iron is transported by mitoferrin, to the mitochondria, 
where heme is synthetized. Iron can also be stored as ferritin (Figure 5) (17).  
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Figure 5 - Incorporation of iron in developing red cells (17). 
 
TFR1 has its highest expression in placenta, erythroid marrow cells and liver, but is 
expressed in most cells. It is a disulfide-linked homodimeric glycoprotein of two 90 kDa 
subunits and is able to bind two TF molecules. Once again the pH dependent affinity of 
TFR1 to TF is an important key to the release of iron in the cells. At the physiological pH 
7.4, the affinity of TFR1 to diferric TF is about 2000 times higher than the affinity of TFR1 
to apotransferrin; once inside the cell, at the endosomal pH of 5.5, the affinity of TFR1 to 
apotransferrin is higher than the affinity to diferric TF, favoring the release of iron from TF 
(10).   
Transferrin is up-regulated by iron deficiency and down-regulated by iron overload, and 
is also influenced by hydrogen peroxide and nitric oxide generated in oxidative stress 
conditions through iron regulatory protein (IRP).  
Accumulation of iron in the body can cause serious damages. Considering that, in 
normal conditions, only 20 - 25 mg of iron is required for erythropoiesis, the regulation of 
iron that is transported from the enterocyte into the blood is very important. If too much iron 
is transported by TF1, its receptor, TFR1, becomes saturated and iron can be deposited in 
other tissues, like hepatocytes and cardiac myocytes, leading to serious problems (10).   
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HFE (hemochromatosis) gene located in chromosome 6 encodes for an atypical major 
histocompability class I protein that heterodimerizes with β-2 microglobulin. Mutations in 
this gene affect HFE function and can lead to iron overload. The normal function of HFE is 
not well established but it is known that it forms a high-affinity complex with TFR1 at the 
enterocytes. TFR1 sequesters HFE to silence its activity. Diferric transferrin competes with 
HFE for the binding to TFR1 and, in this way, when serum transferrin saturation increases 
occurs dissociation of HFE. (10).  
Another receptor for transferrin can be found highly expressed in the liver, the TFR2. It 
is not regulated by iron since it does not have any IRE’s in its UTR, but its expression is 
decreased in iron deficiency and increased in iron overload. It can also bind to iron bound 
to transferrin in a pH dependent manner but with a lower affinity than TFR1 (10, 18).   
 
1.2.1 – Hepcidin 
 
Hepcidin is a 25-amino acid peptide that derives from a precursor pre-prohepcidin of 
84 amino acids that undergoes two enzymatic cleavages. The human hepcidin gene is 
called HAMP and is located in the chromosome 19 (19). Hepcidin was first identified in 
2000, in urine and plasma.    
It has an important role in the regulation of iron absorption in the gastrointestinal tract 
and in iron availability from macrophages of the reticuloendothelial system (RES). Its 
structure is a simple hairpin with 8 cysteines that form 4 disulfide bonds in a ladder-like 
configuration. It is predominantly expressed in the liver but it can be expressed also in other 
tissues, such as in the heart, kidney, adipose tissue, pancreas and hematopoietic cells (20). 
Hepcidin controls iron availability by binding to ferroportin, causing its degradation and 
removal from the surface of cells, thus preventing iron from leaving the cells to bloodstream. 
Besides the role on controlling iron absorption in the gastrointestinal tract it also controls 
iron availability from the reticuloendothelial system, binding to FPN1 present on the 
membranes of the macrophages (21). 
Hepcidin is also a type II acute-phase protein, with some importance in immunity. 
Hepcidin synthesis is increased in response to raised serum iron, iron overload and 
inflammation, and is decreased by iron deficiency, hypoxia and increased erythropoietic 
activity (Figure 6). In normal conditions the expression of hepcidin depends on signaling 
through the BMP/SMAD pathway. Hemojuvelin (HJV) bound to the cell membrane 
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participates as a BMP6 (Bone morphogenic protein 6) coreceptor in the pathway regulating 
hepcidin expression, whereas soluble HJV antagonizes BMP6, which is the master hepcidin 
activator in vivo. The binding of HJV/BMP6 phosphorylates SMADs to form an SMAD-1/-5/-
8-SMAD-4 complex that translocates to the nucleus activating the promoter for hepcidin 
production. Mutations in the genes encoding for these molecules involved in hepcidin 
expression may lead to low serum hepcidin levels that, ultimately, will give rise to 
haemochromatosis (17).  
 It was shown, in mice, that oral administration of iron increases urinary hepcidin 
excretion, in contrast with induced iron deficiency by phlebotomy that reduces hepcidin 
expression (22). 
Inflammation controls hepcidin expression through IL-6 and IL-1β by activating STAT3 
and its binding to a regulatory element in the hepcidin promoter. In humans, recombinant 
IL-6 infusion triggered, in just two hours, a significant increase in urinary hepcidin 
concentration and a decrease in serum iron levels (Figure 6) (17). 
In ineffective erythropoiesis, increased erythroid precursors secrete growth 
differentiation factor 15 (GDF-15) and twisted gastrulation protein homolog 1 (TWSG1) 
which inhibit hepcidin production (Figure 6). Hypoxia inducible factors, that stimulate 
erythropoietin production, control iron homeostasis by downregulation of hepcidin, 
repressing its promoter with the upregulation of ferroportin (Figure 6) (17).    
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Figure 6 - Stimulatory and inhibitory signals of hepcidin regulation (17). 
 
 
 
 
BMP: bone morphogenic protein; FPN: ferroportin; GDF: growth differentiation factor; 
HFE: hemochromatosis; HIF: hypoxia inducible factor; HJV: hemojuvelin; IL: interleukin; 
STAT: signal transducer and activator of transcription; TF: trasnferrin; TFR: transferrin 
receptor; TWSG: twisted gastrulation protein. 
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1.3 – Adipose tissue  
 
The adipose tissue, previously considered as a fat storage only, is now recognized as 
an active endocrine organ that contributes to metabolic control and body homeostasis (23, 
24). In fact, adipose tissue is the energetic storage of our body and is regulated by the 
nervous system, nutrients and hormones, either by autocrine or paracrine fashion that can 
influence other organs and metabolisms (25).  
There are two kinds of adipose tissue, brown and white. Brown adipose tissue is 
principally found in neonates. There are some differences between cells from white adipose 
tissue and brown adipose tissue (24, 25).  
White adipocytes are spherical cells with a diameter from a minimum of 30 to 40 µm to 
a maximum of 150 to 160 µm (lean - subcutaneous adipose tissue) and from a minimum of 
20 to 30 µm to a maximum of 90 to 100 µm (lean - visceral adipose tissue). Most of the 
cytoplasm is occupied by the lipid droplet and only a thin rim of cytoplasm is visible, 
occupied by an elongated mitochondria, Golgi complex, rough and smooth endoplasmic 
reticulum, vesicles and other organelles (Figure 7) (25). 
  
 
B A
B 
Figure 7 - White adipose tissue. (A) Optical microscopy of subcutaneous adipose tissue of 
human white adipose tissue (formaldehyde-fixed and paraffin-embedded). Bar = 30 µm. (B) 
Electron microscopy of murin white adipose tissue. Bar=2 µm (25).  
CAP: capillary lumen; F: fibroblast; L: lipid droplet; M: mitochondria; Ma: macrophage; 
N: nucleus. 
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Brown adipocytes present numerous small vacuoles. They have a polygonal or ellipsoid 
shape with a diameter from a minimum of 15 to 20 µm to a maximum of 40 to 50 µm. 
Whereas white adipocytes only have one elongated mitochondria, brown adipocytes have 
numerous, big and rich mitochondria in transverse cristae. The other organelles are also 
present in these cells. Brown adipocytes are joined by gap junctions. (Figure 8) (23, 25).  
The predominant form of adipocytes found in adults is the white adipose tissue (WAT). 
Different types of cells are present in the WAT, namely, preadipocytes, adipocytes, 
macrophages, endothelial cells, fibroblasts and leukocytes. Due to this multifactorial 
composition, the WAT is an important mediator of several metabolic pathways and of 
inflammation. In the last years, the production of several adipokines by the adipose tissue 
has been reported, including: adiponectin, resistin, visfatin, apelin, vaspin, hepcidin, TNF-
α, chemerin, omentin, monocyte chemoattractant protein-1 (MCP-1) and plasminogen 
activator inhibitor-1 (PAI-1), among others. The different distribution of fat depots in the body 
give rise to different roles, by secreting different sets of adipokines (Figure 9) (24). 
Adipose tissue depots are classified as visceral and subcutaneous according to its 
localization. In small mammals there are two principal subcutaneous depots, anterior and 
posterior, and several visceral depots, located inside the thorax (mediastinic) and abdomen 
(omental, mesenteric, perirenal, retroperitoneal, parametrial, periovaric, epididymal, 
perivescical). These two types of adipose tissue differ on the type of fat cells, endocrine 
function, lipolytic activity and response to insulin. The visceral adipose tissue is 
A B
Figure 8 - Brown adipose tissue. (A) Optical microscopy of human brown adipose tissue. Bar 
= 15 µm (B) Electron microscopy of mouse brown adipose tissue. Bar = 1 µm (25).  
L: lipid droplets; M: mitochondria; N: nucleus. 
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metabolically more active than the subcutaneous adipose tissue, as it produces more 
adipokines and has more macrophages (25, 26).  
Visceral fat venous blood is drained directly to the liver through the portal vein; the 
anatomical proximity provides a direct hepatic access to free fatty acids (FFAs) and 
adipokines. These adipokines activate hepatic immune mechanisms with production of 
inflammatory mediators. The subcutaneous fat venous drainage is performed through 
systemic veins. Visceral adipose tissue is also more vascularized and more heavily 
innervated than subcutaneous adipose tissue (26).   
  
Adipocytes are storage depots of energy, in the form of triglycerides (TGs) droplets. 
New adipocytes avidly absorb FFAs and TGs in the postprandial period; however, once 
they grow larger they become dysfunctional. This larger dysfunctional adipocytes are more 
Specialized 
functions of local 
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IL-6
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TNFα
MCP-1
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Figure 9 - The multiple adipokines produced in white adipose tissue in the different fat depots 
in the body (3).  
FFAs: free fatty acids; IL: interleukin; IL-1Ra: interleukin 1 receptor antagonist; IP-10: 
interferon-inducible protein-10; MCP-1:  monocyte chemoattractant protein-1; RANTES: 
regulated on activation, normal T expressed and secreted; TNFα: tumor necrosis factor 
alpha; WAT: white adipose tissue. 
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abundant in visceral adipose tissue (VAT). The smaller adipocytes, which are more 
abundant in subcutaneous adipose tissue (SCAT), have more avidity for TGs and FFAs 
uptake, preventing their deposition in non-adipose tissue (26).  
 Adipocytes are provided with several receptors that can be activated by three types 
of signals: chemical signals from circulating hormones, chemical signals from adipokines 
and nervous signals in the form of nerve impulses, activating specific adrenergic receptors 
in fat tissue. They synthesize also, as referred before, a large number of adipokines under 
the form of peptides, proteins and cytokines and over 50 adipokines were already identified 
(26-28).  
Mature adipocytes act like an endocrine organ and are able to influence the appetite, 
energy balance, immunity, insulin sensitivity, angiogenesis, blood pressure, lipid 
metabolism and homeostasis, by producing several adipokines (25).   
Leptin is responsible for the control of adipose tissue growth. It controls food intake 
by reducing appetite, body weight and fat stores. It can influence immunity by enhancing T-
helper (Th)1 immune responses, suppressing Th2 immune responses and by increasing 
macrophage activity, leading to production of different cytokines, like TNF-α and IL-6. Leptin 
can also interfere with the antioxidant balance, by increasing the production of reactive 
oxygen-species (ROS) and nitric oxide-synthase (NOS). A reduction in leptin levels leads 
to severe insulin resistance and vascular dysfunction. In obesity, leptin seems to be raised, 
but presents a reduced activity that could be explained by the development of resistance to 
its functions (23, 27).  
Chemerin has a crucial role in adipocyte differentiation and development. It appears 
to act as modulator of the expression of genes involving glucose and lipid homeostasis in 
adipocytes. It has been also associated with several markers of metabolic syndrome, like 
increased body mass index (BMI), triglycerides, blood pressure and insulin resistance (27).    
Visfatin contributes to leukocyte adhesion and to atherogenic plaque instability, and 
appears to have a direct role in vascular dysfunction and inflammation through NOS 
upregulation. Visfatin, mainly produced by visceral adipose tissue, is increased in subjects 
with obesity, type 2 diabetes mellitus, metabolic syndrome and cardiovascular disease (27).  
Retinol-binding protein-4 (RBP-4) and lipocalin-2, two adipokines that belong to the 
lipocalin family, contribute to insulin resistance and atherosclerosis. RBP-4 is also increased 
in obesity and in individuals with type 2 diabetes mellitus. The gene and protein expression 
of lipocalin-2 in visceral adipose tissue is positively associated with inflammation (27).  
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Plasminogen activator inhibitor 1 (PAI-1) is considered a cardiovascular risk factor, 
as it decreases fibrinolytic capacity. PAI-1 and also serum amyloid A (SAA) are increased 
in obesity and associated with systemic inflammation and atherosclerosis (27).  
Angiotensinogen plays a major role on the regulation of blood pressure, through salt 
reabsorption in renal tubules, and on vasoconstriction. It is produced in adipose tissue, and 
is thought to be responsible for systemic hypertension in obese individuals (27).   
Apelin is an adipokine with a positive effect on glucose metabolism and seems to be 
linked to insulin secretion. However, its plasma concentration is raised in obese, 
hyperinsulinemic and type 2 diabetes mellitus individuals (23, 27). 
Increased levels of resistin are associated with atherosclerosis and it has been 
reported that it increases the expression of several pro-inflammatory cytokines, like TNF-α, 
IL-1, IL-6 and IL-12 through a nuclear factor kappa-light-chain-enhancer of activated B cells-
dependent pathway (NF-kB) (23, 27).  
The production of IL-6 by the adipose tissue, in the absence of inflammation, is about 
15-30% of circulating IL-6. It impairs insulin stimulation, associates with obesity-related 
hypertriglyceridemia, by stimulating hepatic secretion of very low-density lipoproteins and 
induces liver production of C reactive protein (CRP) (26, 27).   
Adiponectin seems to have a protective role against metabolic diseases and against 
atherosclerosis. It has anti-inflammatory activity and a protective role against insulin 
resistance.  It inhibits the expression of adhesion molecules and vascular smooth muscle 
cells proliferation and suppresses transformation of macrophages to foam cells. It is 
decreased in patients with abdominal obesity. It induces the production of important anti-
inflammatory factors, such as IL-10 (23, 26, 27). 
Omentin appears to have anti-inflammatory ability by inhibition of NF-kB, reducing 
endothelial dysfunction and atherosclerosis, and also seems to have a role in modulating 
insulin action. The levels of omentin are decreased in obese individuals (23, 27).  
Increased expression of vaspin, a derived serine protease inhibitor from visceral 
adipose tissue, is associated with fat mass expansion and decreases insulin resistance (23, 
27).  
TNF-α, plays an important role in inflammatory cell activation and recruitment, and 
has been linked to insulin resistance in skeletal muscle and adipose tissue, and it seems to 
favor atherosclerosis through inducing adhesion molecules expression in endothelial and 
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vascular smooth muscle cells. It also induces activation of NF-kB factor that regulates an 
array of genes associated with inflammation. Obese individuals have higher circulating 
levels of TNF-α than lean individuals (23, 26, 27, 29).  
 
1.4. – Modulation of erythropoiesis 
 
A relationship is believed to exist between adipose tissue and erythropoiesis. An 
increase in body mass should trigger a stimulus of erythropoiesis, increasing the number of 
erythrocytes to face the higher oxygen requirements. However, apparently because obesity 
is associated with a low-grade inflammatory state, this is not always observed. This 
condition has been named as the “paradox of obesity”, and suggests an undergoing 
erythropoietic disturbance. 
As a consequence of the underlying chronic inflammation in obesity, the production 
of pro-inflammatory adipokines that stimulate hepatic hepcidin production seems to 
influence erythropoiesis (Figure 10). The adipose tissue produces IL-6 that directly 
stimulates hepatic hepcidin production. Indeed, it was found that IL-6 is sufficient for the 
induction of hepcidin during inflammation and that the IL-6-hepcidin axis is responsible for 
the hypoferremia associated with inflammation (15). In a similar way, leptin is capable of 
inducing hepatic hepcidin expression via Jak2/STAT3 signaling pathway (30, 31). 
Moreover, TNF-α, a pro-inflammatory cytokine also produced by adipocytes, is known to 
inhibit erythropoiesis, through inhibition of CFU-e colony formation (Figure 10). Its blood 
levels are elevated in patients with anemia of chronic diseases, and it has been reported 
that exposure to TNF-α produces a similar anemia in either humans or mice, further 
suggesting that TNF-α is implicated in the pathogenesis of this anemia (32). Moreover, TNF-
α stimulates the production of IL-6, triggering the acute phase response that leads to the 
up-regulation of several hepatic inflammatory mediators, such as hepcidin. 
Nowadays, it is known that adipocytes are also capable of producing hepcidin (33). 
However, it remains the doubt if this production influences the circulating levels of hepcidin 
(Figure 10). 
Hepcidin, by diminishing iron absorption and mobilization, will directly influence 
erythropoiesis. It is down-regulated in case of anemia, low iron, hypoxia and high levels of 
erythropoietin, showing a reduction in hepcidin serum and mRNA levels (34, 35). 
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Figure 10 - Contribution of adipose tissue to modulation of erythropoiesis.  
 
An association between obesity and hypoferremia has been reported (36, 37), 
however, the mechanisms linking them are still poorly clarified. The most accepted 
hypothesis is that iron deficiency is a consequence of the chronic low-grade inflammation 
state in obesity (37). As already referred, besides the production of different regulators of 
hepatic hepcidin secretion, such as IL-6 and leptin (19), adipocytes are capable of 
producing hepcidin, affecting directly iron status and inhibiting erythropoiesis (36). If this 
production only becomes relevant in obesity is still a doubt. Thus, there are still 
controversies concerning the contribution of adipocytes to the circulating levels of hepcidin 
and its linkage to erythropoietic disturbances. Besides, the exact mechanism that regulates 
hepcidin expression by the adipose tissue is poorly clarified; it remains the question if 
hepcidin synthesis is stimulated by inflammation, hypoxia or by iron levels, and in the last 
case, which proteins are involved (Figure 11). 
IL-6: interleukin 6; TNF: tumor necrosis factor alpha; “+”: induce; “-“: suppress; “?”: 
doubt. 
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Besides the hematopoietic effects, EPO has several pleiotropic actions, namely, 
cytoprotection, antiapoptotic, anti-inflammatory and angiogenic capacities, but high 
concentrations of EPO are needed to exert them (38). Chronic administration of EPO, in 
rats, in a dose that was insufficient to increase hematocrit, was shown to improve survival, 
repair endothelial damage and preserve renal function (39), suggesting that there is a 
different dose-response relationship for erythropoietic and for pleiotropic effects.  
As reported by some authors, EPO supplementation can increase energy 
expenditure and reduce food intake and fat mass accumulation (40). This raises the 
question, if this reduction in fat mass, induced by EPO, influences the expression of hepcidin 
and of other proteins and adipokines produced by the adipocytes.   
EPO seems to reduce the production of pro-inflammatory cytokines, such as TNF-
α, IL-6 and IL-1β via STAT3/5 signaling. Its actions towards macrophages seems to inhibit 
Figure 11 - Regulation of hepcidin expression by the adipose tissue (37). 
BMP: bone morphogenic protein; DMT1: divalent metal transporter 1; FPN: ferroportin; 
HJV: hemojuvelin; IL: interleukin; MT2: matriptase 2; Neo: neogenin; sHJV: soluble 
hemojuvelin; STAT: signal transducer and activator of transcription; “+”: induce; “-“: 
suppress; “?”: doubt. 
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NF-kB that is a crucial activator for many pro-inflammatory cytokines, namely, TNF- α, IL-
1β, IL-6, IL-12 and IL-23 (38, 41). This EPO action may, therefore, reduce the inflammation 
due to macrophage infiltration in the adipose tissue.   
Chapter 2 – Objectives and work plan 
 
The aim of this study was to clarify the role of subcutaneous and visceral adipose 
tissue in iron metabolism and in erythropoiesis, by using lean, adult, normotensive rats 
under an erythropoietic stimuli along 6 weeks. We induced an erythropoietic stimuli, by 
administering two high doses of rHuEPO (recombinant human erythropoietin) during the 
last 3 weeks of the protocol. 
The rats were randomly divided in 3 groups – control, rHuEPO200 and rHuEPO600. 
Hematological and biochemical studies including markers of renal function, inflammation, 
iron status and lipid profile, were performed at starting (T0) and at the end of the protocol 
(T1). To perform genetic studies in the adipose tissue, we have carefully removed 
subcutaneous and visceral adipose tissue at the end of the study. 
We studied the gene expression of erythropoietic and iron regulatory proteins, such 
as, hepcidin, IL-6, BMP6, EPOR and ferritin, by the visceral and subcutaneous adipose 
tissue.  
We aim to understand the contribution of visceral and subcutaneous adipose tissue 
to the erythropoietic process.  
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Chapter 3 – Materials and methods  
 
3.1. – Animals and experimental protocol 
 
Male Wistar rats (Charles River Lab., Inc., Chatillon-sur-Chalaronne, France), with 
320-350 g of body weight (BW), were maintained in ventilated cages, in an air conditioned 
room, subjected to 12 h dark/light cycles and given free access to rat laboratory chow 
(SAFE-A03, Augy, France)  and tap water. Animal experiments were conducted according 
to the European Communities Council Directives on Animal Care. The experiments 
received the approval by the Ethics Committee of the Faculty of Medicine from the 
University of Coimbra. 
The rats were randomly divided by groups: 1) control - receiving saline solution by 
subcutaneous injection; 2) rHuEPO200 – receiving 200 IU/BW/week of rHuEpo 
(NeoRecormon®, Roche) by subcutaneous injection; 3) rHuEPO600 – receiving 600 
IU/BW/week of rHuEpo (NeoRecormon®, Roche) by subcutaneous injection, during 3 
weeks. BW was monitored throughout the study and blood pressure (BP) and heart rate 
(HR) measures were obtained by the tail-cuff method, using a sphygmomanometer (LE5001 
Pressure meter, Panlab Havard Apparatus, Barcelona, Spain). 
 
3.1.1. – Sample collection  
  
 Blood collection was performed with rats under anesthesia (intraperitoneal) with a 2 
mg/kg BW of a 2:1 (v:v) 50 mg/mL ketamine (Ketalar®, Parke-Davis, Lab. Pfeizer Lda, 
Seixal, Portugal) solution in 2.5% chlorpromazine (Largactil®, Rhône-Poulenc Rorer, Lab. 
Vitória, Amadora, Portugal). Blood was collected at the begging and at the end of the 
protocol, by venipuncuture, from the jugular vein, into Vacuette® tubes without 
anticoagulant (to obtain serum) and with K3EDTA (to obtain plasma) for hematological and 
biochemical studies.  Plasma and serum aliquots were stored at -80ºC until assayed. 
At the end of the protocol and after blood collection, the rats were sacrificed by 
cervical dislocation, and small portions (0.2 g) of subcutaneous and visceral adipose tissue 
were removed from each rat, immediately immersed in RNAlater® solution (Sigma-Aldrich 
Co. LLC. St. Louis, Missouri, USA), and stored at 4 °C for 24h; afterwards, the samples 
were frozen at -20ºC.  
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3.2. – Hematological studies 
  
The hematological determinations using whole blood K3EDTA were performed on 
an automatic blood cell counter (HORIBA ABX, Amadora, Portugal), including the 
concentration of red blood cells (RBC), white blood cell (WBC) and platelets (PLT), mean 
cell volume (MCV), mean cell hemoglobin (MCH), mean cell hemoglobin concentration 
(MCHC), red cell distribution width (RDW), HCT and HGB concentration. Reticulocyte count 
was measured by microscopic counting on blood smears after vital staining with New 
methylene blue (reticulocyte stain; Sigma-Aldrich Co. LLC. St Louis, Missouri, USA).   
Serum levels of EPO were evaluated by rat specific ELISA kit (MyBioSource, San 
Diego, CA, USA). All assays were performed according to the manufacturer’s 
recommendations. 
 
3.3. – Biochemical studies 
 
High-sensitive C-reactive protein (CRP) was determined by using a rat.specific Elisa 
kit from Alpha Diagnostic International (San Antonio, USA). 
The following serum markers were analyzed on a Hitachi 717 analyser (Roche 
Diagnostics Inc., Massachuasetts, USA) using standard methods: creatinine, blood urea 
nitrogen (BUN) and uric acid, as renal function markers; glucose, serum total cholesterol, 
high-density lipoprotein cholesterol (chol-HDL), low-density lipoprotein cholesterol (chol-
LDL), triglycerides as lipid profile markers. Atherogenic index was given by the equation: 
Atherogenic index =
Total cholesterol (mg\dL)
Chol−HDL(mg\dL)
  . Creatine kinase was also analyzed on a Hitachi 
717 analyser (Roche Diagnostics Inc., Massachuasetts, USA) using standard methods. 
Serum iron concentration was determined using a colorimetric method (Iron, Randox 
Laboratories Ltd., North Ireland, UK), whereas serum ferritin and transferrin were measured 
by immunoturbidimetry (Laboratories Ltd., North Ireland, UK). Transferrin saturation was 
determined by the equation: Transferrin saturation % =
Iron (µg\dL) ×100
Transferrin (mg\dL) ×2
 . 
IL-6 was determined by rat specific ELISA kit (Invitrogen, Invitrogen Corporation, 
Camarillo CA).   
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3.4. – Molecular genetic studies 
 
3.4.1. – RNA extraction by TriPure reagent 
 
 All the equipment and materials were prepared to avoid contamination of samples 
with RNAses. To ensure that, we used diethylpyrocarbonate (DEPC) to treat all the metalic 
objects and glassware that would be in touch with the samples. The material was cleaned 
with that detergent and immersed in it for two hours and, finally, heated at 120 ºC for one 
hour.  
 RNA extraction from adipose tissue was performed using a total volume of 1 ml TRI 
Reagent® (Sigma-Aldrich Co. LLC. St. Louis, Missouri, USA) while using a mechanical 
homogenizer. Total RNA isolation was performed as described by the manufacturer. This 
process is based on the single step liquid-phase separation developed by Chomczynski 
and Sacchi (42), by which a Trizol based reagent is added to the tissue and homogenized. 
The reagent disrupts cells and denatures endogenous nucleases, thus preserving the 
integrity of RNA in the sample. The second step is to add chloroform to the extract that, 
after centrifugation, forms three phases: a colorless aqueous (upper) phase, a white 
interphase and the red organic (lower) phase. RNA is recovered from the upper colorless 
aqueous phase by precipitation with isopropanol. Afterwards, the RNA is washed with 
ethanol, resuspended in DEPC treated water, and stored at -80°C until required. 
3.4.2. – RNA concentration and purity 
 
Nucleic acids have maximum absorbance at 260 nm and proteins at 280 nm. The 
RNA concentration was quantified by measuring the absorbance of RNA in water treated 
with DEPC at 260nm using a spectrophotometer NanoDrop1000 (ThermoScientific, 
Wilmington, DE, USA). The concentration was calculated using the following formula: 
 RNA concentration (µg/mL) = A260 x dilution x 40.  
The purity of the RNA was given by the ratio of A260/A280. A ratio between 1.8 and 
2.00 indicates RNA free of contamination of proteins and is generally accepted as “pure”. 
The RNA samples were kept at -80°C until further analyses.  
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3.4.3. – cDNA synthesis 
 
 The synthesis of first-strand cDNA from the RNA extracted was performed according 
to the recommended protocol of the GRS RT-PCR Kit (from GRiSP Research Solutions, 
Porto, Portugal). This kit contains all the required components for the one step RT-PCR 
(reverse transcriptase polymerase chain reaction) and primer extension. This protocol uses 
an engineered M-MLV RT (Molony Murine Leukemia Virus Reverse Transcriptase) that is 
a RNA-dependent DNA polymerase with reduced RNAse H activity and increased thermal 
stability. This kit also includes an RNAse inhibitor to assure no RNA degradation by 
contamination. The protocol requires a first short incubation of the template RNA with 
random hexamer primers (included in the kit) at 70°C and then the final incubation for 60 
minutes at 37°C with the necessary components for the  reaction (First-strand Buffer, dNTP 
MIX, RNAse Inhibitor and M-MLV RT).  
3.4.4. – Gene expression analysis with qPCR 
  
 The gene expression was analyzed by qPCR, performed in the Mini-Opticon Real-
Time PCR System (Bio-Rad Laboratories), and data was analyzed with the software CFX 
Manager™. For the amplification we used the KAPA SYBR® FAST qPCR kit (Kapa 
Biosystems, Inc., Wilmington, MA, USA) and specific primer pairs (Table 1). The qPCR 
reactions were performed using the following conditions: enzyme activation at 95ºC for 30 
seconds; denaturation at 95ºC for 10 seconds; annealing for 20 seconds (for each pair of 
primers, the temperature is referred in Table 1). Gene expression was normalized to alpha-
tubulin gene, and relative quantification was calculated using the 2-ΔΔCT method. 
Table 1 - Primers used on qPCR for gene expression analysis. 
Primer Forward 5’ – 3’ Reverse 5’ – 3’ Mt 
Alpha-
Tubulin 
CACCCGTCTTCAGGGCTTCTTGGTTT CATTTCACCATCTGGTTGGCTGGCTC 59° 
HAMP AAGGCAAGATGGCACTAAGC GAAGTTGGTGTCTCGCTTCC 58° 
IL-6 ATGTTGTTGACAGCCACTGC TTTTCTGACAGTGCATCATCG 58° 
BMP6 GGTGGAGTACGACAAGGAGTT GTCACAACCCACAGATTGCTA 59° 
EPOR CTGCGACTATGGATGAAG GGATGGTGTACTCAAAGC 59° 
Ferritin GCCCTGAAGAACTTTGCCAAAT TGCAGGAAGATTCGTCCACCT 59° 
BMP6: Bone morphogenic protein 6; EPOR: receptor for erythropoietin; IL-6: 
interleukin 6; HAMP: Hepcidin antimicrobial peptide; Mt: melting temperature.   
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3.5. – Statistical analysis 
 
 We used the Statistical Package for Social Sciences (SPSS, version 22 for windows, 
Chicago, IL, USA). A P value lower than 0.05 was considered as statistically significant. 
Comparison between groups were performed using Mann-Whitney U test. Measurements 
are expressed as mean ± standard error of the mean (SEM). The correlation analysis was 
performed by calculating the Spearman coefficient correlation. 
 
 
Chapter 4 – Results  
 
 At starting, the hematological and biochemical values presented by the 3 groups 
were compared to assure that there were no differences between groups.  
 At the end, the control group was used to evaluate the physiological changes along 
the 6 weeks of the protocol and to evaluate the changes induced by the erythropoietic 
stimuli.  
4.1. – Hematological studies 
 
The hematological evaluation at starting (T0) and at the end of the protocol (T1) are 
presented in table 2.  
There were no significant differences in body weight between the three groups of 
rats at the beginning of the study and at the end of 6 weeks, but, as expected, a gain of 
weight was observed, that was similar in the three groups. 
The hematological evaluation, at T0, showed that there were no significant 
differences between the rats randomly included in the three groups of rats. 
We found that after the 6 weeks of the protocol there was a significant physiological 
change to higher values of RBC and RDW and to lower values of MCV and MCH, as showed 
by the control group (control T0 vs control T1). WBC also showed a significant reduction, at 
the end of the protocol.  
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At the end of 6 weeks, the rats from the rHuEPO200 group, when compared with 
the control group, showed significantly higher RBC count, HGB concentration, HCT, RDW, 
MCV and lower MCHC values.  
The rats from rHuEPO600 group, when compared with the control group, at the end 
of the protocol, showed significantly higher WBC, RBC and reticulocyte counts, as well as 
higher values of HGB, HCT, MCV and RDW; significantly lower PLT count and MCHC 
values were also found.  
Comparing the rHuEPO600 group with the rHuEPO200 group, at the end of the 
protocol, we found that the higher dose showed significantly higher values of RBC, HGB, 
HCT, RDW and reticulocytes, and significantly lower platelet count.  
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Table 2 – Body weight and hematological study at the beginning (T0) and at the end (T1) of the protocol for the Control, rHuEPO200 and 
rHuEPO600 groups. 
 
 
 
 
 
 
 
 
 
 
T0 T1 
Control  
(n=10) 
rHuEPO200 
(n=8) 
rHuEPO600 
(n=6) 
Control rHuEPO200  rHuEPO600 
BW (g) 340.50±10.78 365.13±5.26 351.00±9.92 *423.60±13.87  440.63±9.46  418.00±14.55 
RBC (x1012/L) 7.46±0.08 7.54±0.10 7.57±0.13 *7.99±0.17   9.41±0.13 aa   10.84±0.29 aa bb 
HGB (g/dL) 14.36±0.18 14.31±0.21 14.55±0.24 14.47±0.19   17.06±0.32 aa 20.05±0.47 aa bb 
HCT (%) 42.19±0.52 42.58±0.81 42.73±0.91 43.57±0.85   53.21±1.16 aa  64.60±2.13 aa bb 
MCV (fL) 56.70±0.37 56.63±0.68 56.33±1.20 ** 54.50±0.48  56.38±0.92 a 59.50±1.15 aa 
MCH (pg) 19.36±0.15 19.00±0.20 19.25±0.44 ** 18.11±0.19  18.10±0.22 18.50±0.38 
MCHC (g/dL) 34.18±0.21 33.68±0.18 34.07±0.32 33.27±0.35   32.10±0.21 a  31.08±0.42 aa 
RDW (%) 12.25±0.11 12.69±0.34 12.40±0.26 ** 13.34±0.06   15.56±0.17 aa  19.00±0.20 aa bb 
Reticulocytes 
(x109/L) 
228.01±13.21 243.03±17.41 251.47±22.43 205.68±16.16 179.34±26.07  429.87±54.92 a b 
PLT (x109/L) 667.50±18.58 733.00±38.97 713.00±17.04 688.20±19.68 642.38±61.01  482.00±30.76aab 
WBC (x109/L) 4.69±0.34 3.90±0.38 4.25±0.37 ** 3.27±0.30 4.39±0.67 4.12±0.30 a 
Results are presented as mean ± standard error mean. *P< 0.05 and **P< 0.01 for Time 0 vs Time 1. a P< 0.05 and aa P< 0.01 
vs Control. b P< 0.05 and bb P< 0.01 for rHuEPO200 vs rHuEPO600. BW: body weight; HCT: haematocrit; HGB: haemoglobin; 
MCH: mean cell hemoglobin; MCHC: mean cell hemoglobin concentration; MCV: mean cell volume; PLT: platelets; RBC: Red 
blood cells; RDW: red cell distribution width; WBC: white blood cells. 
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4.2. – Study of iron metabolism  
 
Table 3 presents the results of the study for EPO and iron metabolism. 
No significant differences were observed at starting between the 3 groups, except 
for ferritin that was significantly higher in the rHuEPO600 group.  
At the end of the protocol, in control group, we found a physiological significant 
increase in ferritin values, as showed by the control group (T0 vs T1). 
The rHuEPO200 group showed, at the end of the protocol, significantly higher values 
of EPO, when compared with the control group and with the rHuEPO600 group. 
A significant decrease in transferrin values was observed in both rHuEPO groups, 
when compared with the control group.  
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Table 3 – Erythropoietin and iron metabolism at the beginning of the study (T0) and at the end of the protocol (T1), for Control, rHuEPO200 
and rHuEPO600 groups. 
 
 
 T0 T1 
Control 
 (n=10) 
rHuEPO200 
(n=8) 
rHuEPO600 
(n=6) 
Control rHuEPO200 rHuEPO600 
EPO (mUI/mL) 3.93±0.47 3.36±0.25 3.83±0.48 3.85±0.37   6.61±0.58 aa 3.16±0.16 bb 
 
Iron (µg/dL) 192.78±7.66 192.25±16.12 203.33±4.97 183.56±5.83 196.88±16.85 228.00±36.49 
Ferritin (ng/mL) 115.98±7.37 139.95±12.97 164.88±8.24aa * 152.84±7.93 162.70±13.57 181.97±10.49 
Transferrin 
(mg/dL) 
365.03±16.00 346.88±17.38 376.55±16.48 370.32±13.86  316.56±15.4a 296.07±20.42a 
Transferrin 
Saturation (%) 
28.42±2.39 28.20±2.95 27.22±1.19 25.87±1.40 31.45±2.96 40.21±8.22 
Results are presented as mean ± standard error mean. *P< 0.05 and **P< 0.01 for Time 0 vs Time 1. a P< 0.05 and aa P< 0.01 vs Control. 
b P< 0.05 and bb P< 0.01 for rHuEPO200 vs rHuEPO600. EPO: erythropoietin. 
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4.3. – Biochemical studies 
 
 The biochemical evaluation at starting (T0) and at the end of the protocol (T1) are 
presented in table 4. 
At starting (T0) there were some significant differences between the groups, namely, 
urea concentration was higher in rats from groups rHuEPO200 and rHuEPO600, when 
compared with the control group. Significantly higher levels of urea were still observed for 
rHuEPO600 group, at T1, as compared to control.  
Several differences in the lipid profile were observed at starting (T0), as compared 
to the control group; cholesterol and triglycerides were higher in rHuEPO200 group, HDL 
cholesterol levels were higher in both rHuEPO200 and rHuEPO600 groups. At the end of 
the protocol (T1), only HDL cholesterol levels were higher in the rHuEPO200 group when 
compared with the control.  
At T1, rHuEPO200 group showed a creatine kinase (CK) concentration that was 
significantly higher than the control group and significantly lower than the rHuEPO600 
group. 
At the end of the protocol, CRP values were significantly lower in the rHuEPO600 
group, when compared with the rHuEPO200 group. However, serum IL-6 levels, in all 
groups at both times of the study, were above the range of detection (0 – 5.54 pg/mL). 
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Table 4 - Biochemical studies at beginning of the protocol (T0) and at the end of the protocol (T1) for the Control, rHuEPO200 and rHuEPO600 
groups. 
 
T0 T1 
Control 
 (n=10) 
rHuEPO200 
(n=8) 
rHuEPO600 
(n=6) 
Control rHuEPO200 rHuEPO600 
CRP (µg/mL) 786.76±88.56 695.08±65.19 603.83±37.52 736.11±42.74 850.01±88.24  612.06±30.32 b 
 
Urea (mg/dL) 20.15±0.56  22.35±0.47 a 22.73±0.57 a 21.02±0.33 21.70±0.42 23.33±0.76 a 
Creatinine 
(mg/dL) 
0.34±0.01 0.33±0.02 0.34±0.02 0.37±0.02 0.36±0.03 0.40±0.02 
Uric acid (mg/dL) 0.98±0.05 1.14±0.10 1.08±0.19 0.81±0.06 1.18±0.18 1.30±0.22 
 
CK (U/L) 456.29±49.70 570.67±85.13 523.40±125.15 446.86±71.56  90.67±16.72 aa  245.80±67.62 b 
 
Glucose (mg/dL) 181.63±5.00 194.13±15.14 217.17±14.32 168.11±8.76 198.63±23.02 166.83±19.32 
Chol-Total 
(mg/dL) 
53.30±1.90  67.63±5.44 a 61.50±3.60 54.10±2.64 65.13±4.69 55.33±3.26 
Chol-HDL (mg/dL) 28.10±1.29  38.00±4.07 a 34.83±2.73 a 28.00±1.20  35.50±3.56 a 30.50±3.08 
Chol-LDL (mg/dL) 12.60±0.82 15.75±1.63 13.67±0.80 14.13±0.74 16.13±1.30 15.33±1.58 
TGs (mg/dL) 140.10±23.11  189.13±10.85a 157.17±26.06 177.71±12.17 205.75±16.66 166.50±28.87 
Atherogenic index 1.91±0.06 1.83±0.10 1.80±0.10 1.94±0.04 1.86±0.08 1.85±0.12 
Results are presented as mean ± standard error mean. a P< 0.05 and aa P< 0.01 vs Control. b P< 0.05 and bb P< 0.01 for rHuEPO200 vs 
rHuEPO600. CRP – C reactive protein; Chol-HDL: high density lipoprotein cholesterol; Chol-LDL: low density lipoprotein cholesterol; Chol-
Total: total cholesterol; CK: creatine kinase; TGs: triglycerides.  
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4.4. – Gene expression studies 
 
 To study the gene expression of several iron and erythropoietic regulatory factors, 
we used alpha-tubulin gene expression as a housekeeping gene.  
Concerning the subcutaneous adipose tissue, we found that the rHuEPO200 group 
presented a significant overexpression of hepcidin (Figure 12 - A) and ferritin (Figure 12 - 
E) genes and an under expression of IL-6 (Figure 12 – B), BMP6 (Figure 12 – C) and EPOR 
(Figure 12 – D) genes. 
The subcutaneous adipose tissue of the rHuEPO600 group, showed that hepcidin 
(Figure 12 - A), IL-6 (Figure 12 – B) and ferritin (Figure 12 – E) genes were significantly 
overexpressed, while BMP6 (Figure 12 – C) and EPOR (Figure 12 – D) genes were 
significantly under expressed. 
Comparing the gene expression in the subcutaneous adipose tissue of these two 
rHuEPO groups, a significantly increased expression was found for IL-6 gene, in the 
rHuEPO600 group (Figure 12 - B).  
In the visceral adipose tissue of the rHuEPO200 group we found a significant 
overexpression of hepcidin (Figure 13 – A), IL-6 (Figure 13 – B) and ferritin (Figure 13 – E) 
genes and a significant under expression of BMP6 (Figure 13 – C) and EPOR (Figure 13 – 
D) genes. 
For the rHuEPO600 group, the visceral adipose tissue showed a significant under 
expression of all the 5 studied genes (Figure 13). 
Comparing the gene expression of the visceral adipose tissue from the rHuEPO200 
group with that from rHuEPO600 group, we found that the lower rHuEPO dose presented 
a significantly higher expression of hepcidin (Figure 13 – A), IL-6 (Figure 13 – B) and BMP6 
(Figure 13 – C) genes and a trend towards a higher expression of ferritin gene (P = 0.050) 
(Figure 13 - E). 
We also found that hepcidin expression in the visceral adipose tissue was 
significantly and positively correlated with CRP levels, in the rHuEPO200 rats, and with IL-
6 expression (P=0.037; r=0.900), in the rHuEPO600 rats. 
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Figure 12 – rHuEPO effects on relative gene expression mRNA/alpha-tubulin, in 
subcutaneous adipose tissue, of hepcidin – A; IL-6 – B; BMP6 – C; EPOR – D; ferritin -- E. 
Results are presented as mean + standard error.  * P< 0.05, ** P< 0.01 and *** P< 0.001 vs 
Control. # P< 0.05 for rHuEPO200 vs rHuEPO600. 
 
 
 
 
 
Figure 13 - rHuEPO effects on relative gene expression mRNA/alpha-tubulin, in visceral 
adipose tissue, of hepcidin – A; IL-6 – B; BMP6 – C; EPOR – D; ferritin -- E. Results are 
presented as mean + standard error.     * P< 0.05, ** P< 0.01 and *** P< 0.001 vs Control. 
# P< 0.05 for rHuEPO200 vs rHuEPO600. 
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Chapter 5 – Discussion 
 
 It is known that the treatment with recombinant human erythropoietin stimulates 
erythropoiesis leading to an increase in RBC production, hemoglobin concentration and red 
cell volume (1, 43). Indeed, it was reported that rHuEPO has a potent erythropoietic action 
and that in rats is able to cure the anemia caused by renal failure (44).  
\In this study we observed that the administration of rHuEPO in rats results in 
stimulation of erythropoiesis, as shown by the increase in the values of RBC and 
hemoglobin concentration, hematocrit, MCV and RDW. These changes were dose 
dependent, as the group that received a higher dose of rHuEPO presented a higher 
increase in those hematological parameters (e.g. RBC, HGB, HCT and RDW) and in 
reticulocytes, which is in agreement with a higher stimuli of erythropoiesis.  
To maintain the erythropoietic process a correct amount of iron is required (4); 
therefore, a stimuli on erythropoiesis is, usually, associated with a raise in iron mobilization 
and absorption. We found an increase, although not significant, in circulating iron levels in 
both groups (rHuEPO200 and rHuEPO600), as compared to control (T1). This increase in 
iron mobilization was associated with a decrease in transferrin and a trend towards an 
increase in transferrin saturation and ferritin levels. The differences in iron metabolism 
parameters between the two rHuEPO groups were not statistical significant. In accordance, 
Adam et al. (45) reported that iron-loaded rats did not demonstrate an increase in intestinal 
iron absorption with rHuEPO therapy, despite the significant enhancement observed in 
erythropoiesis. 
The erythropoietic stimuli, independently of the dose of recombinant erythropoietin 
administered, did not induce any significant alteration in lipid profile and in the markers of 
renal function. 
Hepcidin is the main regulator of iron absorption and mobilization and its levels are 
dependent on iron status, inflammation, hypoxia and erythropoietic process (4, 21). A strong 
erythropoiesis stimuli triggers a decrease in hepcidin concentrations. The adipose tissue is 
capable of expressing hepcidin, both at mRNA and protein levels (33). Visceral and 
subcutaneous hepcidin mRNA expression is higher in adipose tissue of obese individuals, 
correlating with inflammatory parameters, such as IL-6 and CRP (33). Indeed, the 
expression within the adipose tissue is believed to be regulated by hypoxia and/or 
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inflammation and not by body iron stores (33, 46). Nemeth et al. (22) by performing studies 
in human liver cell cultures, in mice, and in human volunteers concluded that IL-6 is 
sufficient to induce hepcidin production during inflammation and that the IL-6-hepcidin axis 
is responsible for the hypoferremia associated with inflammation. Adipose tissue is known 
to express and release IL-6. Studies in obese (ob/ob line) and lean mice showed 
significantly higher IL-6 levels in obese mice, due to increased IL-6 expression in adipose 
tissue (47).  
As far as we know, the effect of an erythropoietic stimuli, through rHuEPO 
administration, on the expression by the visceral and subcutaneous adipose tissue of 
erythropoietic and iron regulatory proteins gene, such as hepcidin and IL-6, had not been 
studied yet. For hepcidin gene expression, we found an overexpression by subcutaneous 
adipose tissue in both rHuEPO groups, and by visceral adipose tissue in the rHuEPO200 
group. Considering IL-6 gene expression, an overexpression by the subcutaneous adipose 
tissue of the rHuEPO600 rats and by the visceral adipose tissue of the rHuEPO200 group 
was observed.  
Considering ferritin gene expression, it was reported that differentiation of 3T3-L1 
cells into adipocytes associates with a consistent increase of ferritin mRNA expression (48). 
In this study, it was observed that an erythropoietic stimuli associated with an 
overexpression of ferritin gene, except for the rats that received 600 IU/BW/week of 
rHuEPO. 
Teng et al. disclosed, in wild type C57B6 mice, a high level of EPOR expression in 
white adipose tissue, comparatively to other non-hematopoietic tissues (40). We found that 
the expression of EPOR in visceral and subcutaneous adipose tissue of both rHuEPO 
groups was underexpressed. It seems that an erythropoietic stimuli, independently of the 
dose of recombinant erythropoietin administered, induces a lower expression of EPOR 
gene by both adipose tissues, suggesting that rHuEPO, in high doses, do not exercise its 
effects on adipose tissue in a direct way. 
In normal conditions the expression of hepcidin depends on signaling through the 
BMP/SMAD pathway. HJV bounded to the cell membrane in hepatocyte participates as a 
BMP6 coreceptor in this pathway, regulating hepcidin expression, whereas soluble HJV 
antagonizes BMP6, which is the master hepcidin activator in vivo (17). We also studied the 
BMP6 gene expression to inquire if hepcidin expression in adipose tissue submitted to a 
erythropoietic stimuli could suffer a similar regulation, but the BMP6 gene was 
underexpressed by subcutaneous and visceral adipose tissues in both rHuEPO groups. 
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Our data suggests that hepcidin expression in adipose tissue is probably regulated by 
inflammation and/or hypoxia, which is in accordance with other reports (33, 46), and that 
the BMP/SMAD pathway do not seem to have an important role in the regulation of 
adipocyte hepcidin expression. 
When comparing data of visceral adipose tissue from the two rHuEPO groups, we 
found that a higher erythropoietic stimuli associates with a significantly lower expression of 
both hepcidin and IL-6 genes. Apparently, the stimuli of erythropoiesis by a higher dose of 
recombinant erythropoietin affects not only the production of hepcidin by the liver (4, 21), 
but also the production of hepcidin by the visceral adipose tissue. Moreover, a significant 
positive correlation was observed between hepcidin gene and IL-6 gene expression in the 
visceral adipose tissue of rHuEPO600 group. A similar correlation between the gene 
expression of hepcidin and IL-6 was reported in a study performed in lean and obese mice 
by Gotardo et al. (49); they found also that the mRNA levels of both hepcidin and IL-6 were 
increased in visceral adipose tissue of obese mice. Our data suggest that under a high 
erythropoietic stimuli, IL-6 and hepcidin expression in visceral adipose tissue are tightly 
associated. 
Comparing data from subcutaneous adipose tissue of the two rHuEPO groups, a 
significantly higher IL-6 gene expression and an increased hepcidin gene expression, 
although not significant, were detected in rHuEPO600 group, as compared to the 
rHuEPO200 group. It seems that the response to a higher erythropoietic stimuli, as the 
rHuEPO600 group underwent, is not the same in subcutaneous adipose tissue and in 
visceral adipose tissue.  
Teng et al. (40) reported that erythropoietin administration decreases fat mass 
accumulation. In accordance, we found that the group of rats under a higher dose of 
rHuEPO showed at the end of the protocol less visceral adipose tissue accumulation than 
the group with lower dosage of rHuEPO (data not shown). Since no differences in the values 
of body weight were detected between the 2 rHuEPO groups, an increase in muscle mass 
may have occurred, which could be related with the higher CK circulating levels found for 
the rHuEPO600 group. 
The different response observed in the two tissues after administration of 600 
IU/BW/week of rHuEPO, may be related to the lower mass of visceral adipose tissue found 
for the rHuEPO600 group of rats. A decrease in visceral mass, accompanied by a reduction 
in its metabolic activity, may be associated with a lower IL-6 expression. Considering that 
inflammation may be the principal regulator of adipocyte hepcidin expression (33, 46), and 
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that our data showed that IL-6 and hepcidin expression are positively related, a reduction 
in IL-6 may induce a down-regulation in hepcidin expression in visceral adipose tissue. 
As referred, a higher erythropoietic stimuli induced a significant increase in 
hematocrit, leading thus to higher blood viscosity. Visceral adipose tissue is metabolically 
more active and more vascularized than the subcutaneous adipose tissue. It is possible that 
the enhanced blood viscosity induces some stasis within the visceral adipose tissue leading 
to hypoxia. Hypoxia is known to reduce hepcidin expression (50); thus, the down-regulation 
of hepcidin found in visceral adipose tissue after a higher dose of recombinant 
erythropoietin might be a consequence of a hypoxic environment.  
This study involves relatively small groups of rats, thus, further studies are warranted 
with a larger population in order to confirm our results. It was not possible to compare the 
gene expression between the two tissues, however it would be of interest in a future work 
to evaluate and compare the gene expression and the proteins produced by the visceral 
and subcutaneous adipose tissue. It is not well established if the production of hepcidin by 
the adipose tissue is reflected in alterations at circulating level and, therefore, if it is enough 
to influence iron absorption or even erythropoiesis. It has been speculated that in obese 
individuals, in whom the amount of adipose tissue is superior, the production of hepcidin by 
adipose tissue has an important impact in hepcidin circulating levels. It would be of interest 
to evaluate if a higher erythropoietic stimuli induces not only a decrease in the expression 
of IL-6 and, consequently, of hepcidin by the visceral adipose tissue. 
In summary, the BMP/SMAD pathway does not seem to have an important role in 
the regulation of hepcidin expression, in adipocyte. When submitted to an erythropoietic 
stimuli the visceral and the subcutaneous adipose tissue respond differently. In the visceral 
adipose tissue, a higher erythropoietic stimuli associates with a lower expression of hepcidin 
and IL-6. Moreover, a positive correlation between hepcidin and IL-6 gene expression was 
found in the visceral adipose tissue of rats submitted to a higher dose of rHuEPO, 
suggesting that under a high erythropoietic stimuli, IL-6 and hepcidin expression are tightly 
related.  
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